Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
about
NK Cell Influence on the Outcome of Primary Epstein-Barr Virus InfectionToward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.Dendritic cells during Epstein Barr virus infection.Controlling cytomegalovirus: helping the immune system take the leadImmunotherapy for post-transplant lymphoproliferative disease.Cytotoxic T lymphocytes as immune-therapy in haematological practice.Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytesAdoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodT cell-based therapies for EBV-associated malignancies.Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.Soluble factors produced by activated CD4+ T cells modulate EBV latency.CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.Cellular immunotherapy for viral infection after HSC transplantation.Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro.Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection.Polyomavirus-associated nephropathy: update on BK virus-specific immunity.Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferationTargeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.Improving the outcome of cord blood transplantation: use of mobilized HSC and other cells from third party donors.Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity.Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.A registry of HLA-typed donors for production of virus-specific CD4 and CD8 T lymphocytes for adoptive reconstitution of immune-compromised patients.Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children.Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target
P2860
Q28069456-37F2F43B-232E-43D1-B06D-F2EC412B090FQ33633262-A9809BE7-DE6D-4763-835F-9EDCBA860AF0Q33782152-F56523DF-F4D2-4BC6-B1D2-365A22753E0CQ33820695-DBDCA1BA-3A01-4993-9E3E-6B065DD77096Q34786255-6E90C2A6-24E4-4C2E-9333-FBB0741A4740Q35157540-EEAD2DB2-A3E5-4FFC-B8C0-F2F88669130DQ35522878-C74D435B-CA63-4EF4-8588-5139FECE06FBQ35582326-AAF7E7B9-29CA-4F17-9DE7-0BB713EA4DF0Q35609768-F0AC5D86-455F-4058-8C67-A58F1A51E305Q35686137-698FC7A8-5AB4-410F-A12D-8A35D499CBE2Q35749824-78E275EF-4602-46D4-A2F4-F8F5137AB856Q35776868-DD86652A-19DA-498C-9D73-CB130E815C58Q35998792-E21CA91D-08B0-4533-BCC0-9C85CF8C6A34Q36371518-99CAD3CB-3552-4F0C-8553-D52DC89F6EE0Q36415765-25A4C09D-EEE1-4E90-ACAC-047A567F96BEQ36492414-440E0A01-BA9C-47E5-9AE9-0C0147DB1EDFQ36556729-3779BF74-A7FA-43E9-A90D-0963F1B519BCQ36890569-C66B2FC0-049A-4348-A0CD-987687F33708Q37220602-E60D7369-A579-4DFE-85FA-489360366AC1Q37592177-24E5BA32-0CFC-42C3-83C7-C859F0AC881CQ37606554-648E7149-13F3-4EF1-BFA5-2989E551BD22Q39966752-3C140AA1-6DC3-4EF6-9DDD-ABA47BE63812Q40687538-C293D37E-1C2A-4E64-ABB0-BA0154C6FEBDQ42176262-863A614C-970F-4F04-AECA-18CA18A77851Q42205114-2C5245EE-EA55-471E-B2C1-22318A0A31FEQ42723067-1BFCBCE2-0B2C-4EC4-A76E-04293351457EQ51981530-18C641A3-BC76-4E1D-B588-6315044B5F89Q52005257-C8B10493-B3C4-4325-AE96-B2A094A8C9F2Q57176933-AE4F0080-9921-4874-86A3-83DC12B0350E
P2860
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
@en
type
label
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
@en
prefLabel
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
@en
P2093
P1476
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
@en
P2093
Adrian P Gee
April G Durett
Barbara Savoldo
Cliona M Rooney
Helen E Heslop
Lopez Teresita
M Helen Huls
Malcolm K Brenner
Michael L Cubbage
P304
P356
10.4049/JIMMUNOL.168.2.909
P407
P577
2002-01-01T00:00:00Z